• STUDIES
    Participation is open to worldwide institutions.
    Read More
  • MEETINGS
    Since 1998, an Annual Meeting of the IELSG investigators has been regularly held.
    Read More
  • NEWSLETTER
    The IELSG Newsletter informs about studies, meetings and other research activities.
    Read More
  • PUBLICATIONS
    The results are presented to major congresses and published into peer-reviewed journals.
    Read More

Fighting cancer through research. You can support us by making a donation, however large or small.

Support Us

LATEST NEWS

  • IELSG Studies presented during 17-ICML

    Oral presentations
    IELSG37 – A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy
    IELSG39 – The IELSG39 trial: efficacy of first-line chlamydia psitaci eradication with a six-month regimen of doxycycline in patients with stage-I MALT lymphoma of ocular adnexae
    IELSG43 – Consolidative HCT-ASCT is superior to non-myeloablative chemo-immuotherapy in newly-diagnosed PCNSL – Updated results of the randomized phase IIMATRix/IELSG43 trial
    IELSG47 – Rituximab and ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IESLG47/MALIBU phase II study

    Poster presentation
    IELSG35 – Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group

  • IELSG Annual Meeting 2024

    The next Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 8-9, 2024 in Stresa (Italy) at Hotel La Palma.

    More information will follow soon.


ONGOING STUDIES

  • IELSG50
    IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy Participants required: 30 … Read more
  • IELSG49
    IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 … Read more
  • IELSG44
    IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): … Read more

LATEST NEWSLETTER

PUBLICATIONS

Top